Detalles del proyecto
Descripción
Summary
The purpose of the Recombinant Virus Core C is to generate quality controlled recombinant herpesviruses for
KSHV, EBV, and MHV68 (Projects 1, 2 and 3). The services of Core C will continue to aid the overall goal of
the program project to comprehensively analyze the role of herpesvirus non-coding RNAs as well as studies on
host cellular lncRNAs that are perturbed in response to viral infection. In addition to constructing recombinant
viruses, Core C will perform genome-wide sequencing of viral mutants. Building upon years of experience in
making a complete set of KSHV miRNA deletion mutants, our group has developed and implemented techniques
for making bacmid-derived mutants in both KSHV and MHV68, and more recently also EBV. During the first
funding period we designed, created and quality controlled more than 60 recombinant herpesviruses. Additional
services and innovations are target enriched re-sequencing of latently infected producer cell lines for EBV and
KSHV and applying innovative CRISPR technologies for mutagenesis.
The purpose of the Recombinant Virus Core C is to generate quality controlled recombinant herpesviruses for
KSHV, EBV, and MHV68 (Projects 1, 2 and 3). The services of Core C will continue to aid the overall goal of
the program project to comprehensively analyze the role of herpesvirus non-coding RNAs as well as studies on
host cellular lncRNAs that are perturbed in response to viral infection. In addition to constructing recombinant
viruses, Core C will perform genome-wide sequencing of viral mutants. Building upon years of experience in
making a complete set of KSHV miRNA deletion mutants, our group has developed and implemented techniques
for making bacmid-derived mutants in both KSHV and MHV68, and more recently also EBV. During the first
funding period we designed, created and quality controlled more than 60 recombinant herpesviruses. Additional
services and innovations are target enriched re-sequencing of latently infected producer cell lines for EBV and
KSHV and applying innovative CRISPR technologies for mutagenesis.
Estado | Activo |
---|---|
Fecha de inicio/Fecha fin | 1/2/24 → 31/1/25 |
Enlaces | https://projectreporter.nih.gov/project_info_details.cfm?aid=10770572 |
Financiación
- National Cancer Institute: USD139,481.00
!!!ASJC Scopus Subject Areas
- Genética
- Enfermedades infecciosas
Huella digital
Explore los temas de investigación que se abordan en este proyecto. Estas etiquetas se generan con base en las adjudicaciones/concesiones subyacentes. Juntos, forma una huella digital única.